NCT01768117View on ClinicalTrials.gov

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Meningitis, Meningococcal, Serogroup B
Interventions
BIOLOGICAL

rLP2086

0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months

Trial Locations (1)

07601

Frontage Clinical Services (Formally ABR), Hackensack

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01768117 - Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age | Biotech Hunter | Biotech Hunter